Andrew E Beck

US Patent:

8650186, Feb 11, 2014

Filed:

Jul 30, 2010

Appl. No.:

12/846895

Inventors:

Andrew E. Beck - San Diego CA, US
Geoffrey Boeing - San Diego CA, US
Debra L. Shannon - San Diego CA, US

Assignee:

Accenture Global Services Limited - Dublin

International Classification:

G06F 7/00
G06F 17/30

US Classification:

707723, 707771

Abstract:

The present disclosure relates to systems and methods for improving the management of requirements in systems and systems of systems. Multiple requirements databases may be interfaced, and language processing tools may be used to identify requirements having related content. The relevancy of requirements may be based on the semantic distance between terms in the network, their semantic relations, the number of related terms in the requirements, etc. A user may be presented with a navigable cross-section of requirements data relevant to search terms. Thus, added visibility and ease of access is provided for systems and systems of systems.

US Patent:

20230099074, Mar 30, 2023

Filed:

Oct 26, 2022

Appl. No.:

18/049711

Inventors:

- Rahway NJ, US
- La Jolla CA, US
Jeffrey Kern - Gilbertsville PA, US
Linda Liang - Mountain View CA, US
Sanjiv Shah - Wakefield MA, US
Dennis Zaller - Boston MA, US
Andrew Beck - San Diego CA, US
Dennis Gately - San Diego CA, US
Nick Knudsen - Escondido CA, US
Anthony Manibusan - San Diego CA, US
Jianing Wang - San Diego CA, US
Ying Sun - San Diego CA, US

Assignee:

Merck Sharp & Dohme LLC - Rahway NJ
Ambrx, Inc. - La Jolla CA

International Classification:

A61K 47/68
C07K 16/28

Abstract:

Antibody drug conjugates (ADCs) comprising an antibody conjugated to an anti-inflammatory therapeutic agent via a phosphate-based linker with tunable extracellular and intracellular stability are described.

US Patent:

20200164085, May 28, 2020

Filed:

Sep 30, 2016

Appl. No.:

15/765515

Inventors:

- Rahway NJ, US
- La Jolla CA, US
Jeffrey Kern - Gilbertsville PA, US
Linda Liang - Mountain View CA, US
Sanjiv Shah - Wakefield MA, US
Dennis Zaller - Boston MA, US
Andrew Beck - San Diego CA, US
Dennis Gately - San Diego CA, US
Nick Knudsen - Escondido CA, US
Anthony Manibusan - San Diego CA, US
Jianing Wang - San Diego CA, US
Ying Sun - San Diego CA, US

International Classification:

A61K 47/68
C07K 16/28

Abstract:

Antibody drug conjugates (ADCs) comprising an antibody conjugated to an anti-inflammatory therapeutic agent via a phosphate-based linker with tunable extracellular and intracellular stability are described.

US Patent:

20170182181, Jun 29, 2017

Filed:

Mar 30, 2015

Appl. No.:

15/301564

Inventors:

- Rahway NJ, US
- La Jolla CA, US
Philip E. Brandish - Needham MA, US
Sanjiv Shah - Wakefield MA, US
Linda Liang - Mountain View CA, US
Ying Sun - San Diego CA, US
Jianing Wang - San Diego CA, US
Nick Knudsen - Escondido CA, US
Andrew Beck - San Diego CA, US
Anthony Manibusan - San Diego CA, US
Dennis Gately - San Diego CA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
Ambrx, Inc. - La Jolla CA

International Classification:

A61K 47/48
C07K 16/28
C07J 41/00
C07J 43/00

Abstract:

Phosphate-based linkers with tunable stability for intracellular delivery of drug conjugates are described. The phosphate-based linkers comprise a monophosphate, diphosphate, triphosphate, or tetraphosphate group (phosphate group) and a linker arm comprising a tuning element and optionally a spacer. A payload is covalently linked to the phosphate group at the distal end of the linker arm and the functional group at the proximal end of the linker arm is covalently linked to a cell-specific targeting ligand such as an antibody. These phosphate-based linkers have a differentiated and tunable stability in blood vs. an intracellular environment (e.g. lysosomal compartment).

US Patent:

20150152187, Jun 4, 2015

Filed:

Jun 14, 2013

Appl. No.:

14/407792

Inventors:

- La Jolla CA, US
Ning Zou - San Diego CA, US
Amha Hewet - Chula Vista CA, US
Jason K. Pinkstaff - San Rafael CA, US
Shailaja Srinagesh - San Mateo CA, US
Richard S. Barnett - San Marcos CA, US
Feng Tian - San Diego CA, US
Anna-Maria A. Hays Putnam - San Diego CA, US
Marco Gymnopoulos - San Diego CA, US
Nick Knudsen - Escondido CA, US
Andrew Beck - San Diego CA, US

Assignee:

Ambrx, Inc. - La Jolla CA

International Classification:

C07K 16/30
A61K 47/48

Abstract:

This invention relates to anti-prostate-specific membrane antigen antibodies (αPSMA) and αPSMA antibody—nuclear receptor ligand (NRL) conjugates comprising at least one non-naturally-encoded amino acid.

US Patent:

20150152190, Jun 4, 2015

Filed:

Jun 7, 2013

Appl. No.:

14/406190

Inventors:

- La Jolla CA, US
Feng Tian - San Diego CA, US
Anna-Maria A. Hays Putnam - San Diego CA, US
Marco Gymnopoulos - San Diego CA, US
Nick Knudsen - Escondido CA, US
Andrew Beck - San Diego CA, US
Ying Sun - San Diego CA, US

Assignee:

Ambrx, Inc. - La Jolla CA

International Classification:

C07K 16/40
C07K 7/06

Abstract:

This invention relates to prostate-specific membrane antigen (PSMA) antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are αPSMA antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the αPSMA antibodies of the invention are conjugated to one or more toxins. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, dolastatin analogs, and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology uses.